Concord Biotech Ltd.
NSE: CONCORDBIO · Pharmaceuticals
Snapshot
Unlock Concord Biotech Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Biotech Limited is a biopharmaceutical company specialising in the research, development, and manufacturing of fermentation-based active pharmaceutical ingredients (APIs). Its product portfolio spans therapeutic areas including immunosuppressants, oncology, anti-bacterials, and anti-fungals, alongside contract research and manufacturing services.
Business Model
The company generates revenue through the sale of complex fermentation-based APIs to global pharmaceutical markets and by providing contract research and manufacturing services. It leverages its expertise in fermentation and semi-synthesis to serve both domestic and international clients.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of its fermentation-based product portfolio and the increasing demand for complex APIs in global therapeutic markets. The company continues to focus on its contract research and manufacturing capabilities to capture additional market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards, and any failure to maintain compliance could lead to product recalls or manufacturing site restrictions.
- Manufacturing Complexity. The reliance on complex fermentation processes introduces operational risks, including potential yield fluctuations and technical challenges in scaling production.
- Market Competition. The pharmaceutical API sector is highly competitive, with pricing pressures from global generic manufacturers impacting profit margins.
- Geopolitical and Trade Risks. As an exporter, the company faces risks related to international trade policies, currency fluctuations, and changing regulatory requirements in foreign markets.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Concord Biotech Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,055 Cr
TTM · consolidated
NET PROFIT
₹259 Cr
TTM · consolidated
EPS
₹24.78
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.0%
TTM · consolidated
P/E
54.3x
Q4 FY26 · consolidated
EV/EBITDA
33.5x
Q4 FY26 · consolidated
EBITDA MARGIN
39.8%
TTM · consolidated
NET PROFIT MARGIN
27.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Concord Biotech Ltd.CONCORDBIO | 10,890 | 54.32 | 33.52 | -12.1% | 39.8% | 13.9% | 18.0% | -26.8% |
Caplin Point Laboratories Ltd.CAPLIPOINT | 12,103 | 31.67 | 23.06 | 12.9% | 40.1% | 21.4% | 26.0% | +28.5% |
Alivus LifeALIVUS | 11,958 | 25.31 | 16.66 | 6.9% | 33.6% | 19.2% | 24.6% | +9.2% |
Cohance Lifesciences Ltd.COHANCE | 11,471 | 73.99 | 28.98 | 135.3% | 20.8% | 8.7% | 9.7% | -58.5% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | 9,646 | 40.71 | 28.71 | 40.1% | 37.7% | 85.8% | 104.9% | -11.3% |
Corona RemediesCORONA | 9,638 | — | — | — | 21.0% | — | — | — |
As of Q4 FY26
Financials
Concord Biotech Ltd.
NSE: CONCORDBIO · Pharmaceuticals
Snapshot
Unlock Concord Biotech Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Concord Biotech Limited is a biopharmaceutical company specialising in the research, development, and manufacturing of fermentation-based active pharmaceutical ingredients (APIs). Its product portfolio spans therapeutic areas including immunosuppressants, oncology, anti-bacterials, and anti-fungals, alongside contract research and manufacturing services.
Business Model
The company generates revenue through the sale of complex fermentation-based APIs to global pharmaceutical markets and by providing contract research and manufacturing services. It leverages its expertise in fermentation and semi-synthesis to serve both domestic and international clients.
- Incorporation Year:1984
Growth Outlook
Growth is driven by the expansion of its fermentation-based product portfolio and the increasing demand for complex APIs in global therapeutic markets. The company continues to focus on its contract research and manufacturing capabilities to capture additional market share.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards, and any failure to maintain compliance could lead to product recalls or manufacturing site restrictions.
- Manufacturing Complexity. The reliance on complex fermentation processes introduces operational risks, including potential yield fluctuations and technical challenges in scaling production.
- Market Competition. The pharmaceutical API sector is highly competitive, with pricing pressures from global generic manufacturers impacting profit margins.
- Geopolitical and Trade Risks. As an exporter, the company faces risks related to international trade policies, currency fluctuations, and changing regulatory requirements in foreign markets.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Concord Biotech Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,055 Cr
TTM · consolidated
NET PROFIT
₹259 Cr
TTM · consolidated
EPS
₹24.78
TTM · consolidated
RETURN ON EQUITY
13.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.0%
TTM · consolidated
P/E
54.3x
Q4 FY26 · consolidated
EV/EBITDA
33.5x
Q4 FY26 · consolidated
EBITDA MARGIN
39.8%
TTM · consolidated
NET PROFIT MARGIN
27.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.0x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26